Ticker: CING

Cingulate Inc. (NASDAQ: CING) - Quick take Cingulate is a pre-revenue biopharma developing once‑daily ADHD and anxiety therapies using its PTR platform. The company submitted an NDA for lead asset CTx‑1301 on July 31, 2025 (post‑period) and shows progress on financing, but remains loss‑making wit...